Abrev Biotechnology Co., Ltd. has been devoted in the field of antibody discovery and antibody engineering. Abrev’s headquarter is located in Nanjing, China, with production and operation centers in Nanjing, Suzhou, and New Jersey. Abrev has invented unique antibody induction platform technology - UniversalAntigenTM (inducing antibody specific for the epitope of less than five amino acids) and has developed advanced camel single domain antibodies (SdAb) platform technology.
Abrev gathered experienced scientists from China, United States, Japan and so on. Abrev provides contract research antibody services including sdAb production, antibody affinity maturation, antibody humanization, antibody sequencing, detection of antibody affinity, antibody expression, AAV viral vector package and more. Abrev strives to serve as a reliable research partner in antibody development.
